|
1
|
Hsu KF, Wu CL, Huang SC, et al:
Conditionally replicating E1B-deleted adenovirus driven by the
squamous cell carcinoma antigen 2 promoter for uterine cervical
cancer therapy. Cancer Gene Ther. 15:526–534. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lang HC and Wu SL: Lifetime costs of the
top five cancers in Taiwan. Eur J Health Econ. Mar 27–2011.(Epub
ahead of print).
|
|
3
|
Chen CC, Lin JC, Jan JS, Ho SC and Wang L:
Definitive intensity-modulated radiation therapy with concurrent
chemotherapy for patients with locally advanced cervical cancer.
Gynecol Oncol. Apr 22–2011.(Epub ahead of print).
|
|
4
|
Schiffman M, Wentzensen N, Wacholder S,
Kinney W, Gage JC and Castle PE: Human papillomavirus testing in
the prevention of cervical cancer. J Natl Cancer Inst. 103:368–383.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mühlen S, Behren A, Iftner T and Simon C:
Influence of HPV16 E2 and its localisation on the expression of
matrix metalloproteinase-9. Int J Oncol. 37:337–345.
2010.PubMed/NCBI
|
|
6
|
Chen GJ and Forough R: Fibroblast growth
factors, fibroblast growth factor receptors, diseases, and drugs.
Recent Pat Cardiovasc Drug Discov. 1:211–224. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ucuzian AA, Brewster LP, East AT, Pang Y,
Gassman AA and Greisler HP: Characterization of the chemotactic and
mitogenic response of SMCs to PDGF-BB and FGF-2 in fibrin
hydrogels. J Biomed Mater Res A. 94:988–996. 2010.PubMed/NCBI
|
|
8
|
Dorey K and Amaya E: FGF signalling:
diverse roles during early vertebrate embryogenesis. Development.
137:3731–3742. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Caverzasio J and Thouverey C: Activation
of FGF receptors is a new mechanism by which strontium ranelate
induces osteoblastic cell growth. Cell Physiol Biochem. 27:243–250.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Knights V and Cook SJ: De-regulated FGF
receptors as therapeutic targets in cancer. Pharmacol Ther.
125:105–117. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pardo OE, Latigo J, Jeffery RE, et al: The
fibroblast growth factor receptor inhibitor PD173074 blocks small
cell lung cancer growth in vitro and in vivo. Cancer Res.
69:8645–8651. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tsimafeyeu I, Demidov L, Stepanova E, Wynn
N and Ta H: Overexpression of fibroblast growth factor receptors
FGFR1 and FGFR2 in renal cell carcinoma. Scand J Urol Nephrol.
45:190–195. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Katoh M and Katoh M: FGF signaling network
in the gastrointestinal tract. Int J Oncol. 29:163–168.
2006.PubMed/NCBI
|
|
14
|
Yura Y, Yoshioka Y, Yamamoto S, et al:
Enhancing effects of fibroblast growth factor on the proliferation
of salivary gland carcinoma cells and salivary gland
carcinogenesis. J Oral Pathol Med. 30:159–167. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Manuvakhova M, Thottassery JV, Hays S, et
al: Expression of the SNT-1/FRS2 phosphotyrosine binding domain
inhibits activation of MAP kinase and PI3-kinase pathways and
antiestrogen resistant growth induced by FGF-1 in human breast
carcinoma cells. Oncogene. 25:6003–6014. 2006. View Article : Google Scholar
|
|
16
|
Schwertfeger KL: Fibroblast growth factors
in development and cancer: insights from the mammary and prostate
glands. Curr Drug Targets. 10:632–644. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Vodyanik MA, Yu J, Zhang X, et al: A
mesoderm-derived precursor for mesenchymal stem and endothelial
cells. Cell Stem Cell. 7:718–729. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Morrison GM, Oikonomopoulou I, Migueles
RP, et al: Anterior definitive endoderm from ESCs reveals a role
for FGF signaling. Cell Stem Cell. 3:402–415. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hardy KM, Yatskievych TA, Konieczka J,
Bobbs AS and Antin PB: FGF signalling through RAS/MAPK and PI3K
pathways regulates cell movement and gene expression in the chicken
primitive streak without affecting E-cadherin expression. BMC Dev
Biol. 11:202011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Katoh M: Network of WNT and other
regulatory signaling cascades in pluripotent stem cells and cancer
stem cells. Curr Pharm Biotechnol. 12:160–170. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chou CY, Chen YH, Tzeng CC, Cheng YC,
Chang CF and Chen TM: Establishment and characterization of a
human-papillomavirus negative, p53-mutation negative human cervical
cancer cell line. Cancer Lett. 102:173–181. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Benton G, Kleinman HK, George J and
Arnaoutova I: Multiple uses of basement membrane-like matrix
(BME/Matrigel) in vitro and in vivo with cancer cells. Int J
Cancer. 128:1751–1757. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hasimu A, Ge L, Li QZ, Zhang RP and Guo X:
Expressions of Toll-like receptors 3, 4, 7, and 9 in cervical
lesions and their correlation with HPV16 infection in Uighur women.
Chin J Cancer. 30:344–350. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Simionescu C, Mărgăritescu C, Stepan A,
Georgescu CV, Niculescu M and Muntean M: The utility of p16,
E-cadherin and Ki67 in cervical squamous intraepithelial lesions
diagnosis. Rom J Morphol Embryol. 51:621–626. 2010.PubMed/NCBI
|
|
25
|
De Chiara A, Losito S, Terracciano L, Di
Giacomo R, Iaccarino G and Rubolotta MR: Primary plasmacytoma of
the breast. Arch Pathol Lab Med. 125:1078–1080. 2001.
|
|
26
|
Sun H, Qin M, Xiao Y, Yang F, Ni W and Liu
S: Haemangiomas, leiomyosarcoma and myeloma caused by subgroup J
avian leukosis virus in a commercial layer flock. Acta Vet Hung.
58:441–451. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhu QS, Rosenblatt K, Huang KL, et al:
Vimentin is a novel AKT1 target mediating motility and invasion.
Oncogene. 30:457–470. 2011. View Article : Google Scholar : PubMed/NCBI
|
